175 related articles for article (PubMed ID: 21871510)
1. An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo.
Seo DW; Saxinger WC; Guedez L; Cantelmo AR; Albini A; Stetler-Stevenson WG
Peptides; 2011 Sep; 32(9):1840-8. PubMed ID: 21871510
[TBL] [Abstract][Full Text] [Related]
2. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor.
Fernández CA; Butterfield C; Jackson G; Moses MA
J Biol Chem; 2003 Oct; 278(42):40989-95. PubMed ID: 12900406
[TBL] [Abstract][Full Text] [Related]
3. TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism.
Seo DW; Li H; Guedez L; Wingfield PT; Diaz T; Salloum R; Wei BY; Stetler-Stevenson WG
Cell; 2003 Jul; 114(2):171-80. PubMed ID: 12887919
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of VEGF-A-induced increase in vascular permeability by an integrin α3β1-Shp-1-cAMP/PKA pathway.
Kim SH; Cho YR; Kim HJ; Oh JS; Ahn EK; Ko HJ; Hwang BJ; Lee SJ; Cho Y; Kim YK; Stetler-Stevenson WG; Seo DW
Blood; 2012 Dec; 120(24):4892-902. PubMed ID: 23074279
[TBL] [Abstract][Full Text] [Related]
5. Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.
Qi JH; Ebrahem Q; Ali M; Cutler A; Bell B; Prayson N; Sears J; Knauper V; Murphy G; Anand-Apte B
PLoS One; 2013; 8(3):e55667. PubMed ID: 23469166
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy.
Benelli R; Adatia R; Ensoli B; Stetler-Stevenson WG; Santi L; Albini A
Oncol Res; 1994; 6(6):251-7. PubMed ID: 7532474
[TBL] [Abstract][Full Text] [Related]
7. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis.
Boosani CS; Mannam AP; Cosgrove D; Silva R; Hodivala-Dilke KM; Keshamouni VG; Sudhakar A
Blood; 2007 Aug; 110(4):1168-77. PubMed ID: 17426256
[TBL] [Abstract][Full Text] [Related]
8. Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF.
da Silva RG; Tavora B; Robinson SD; Reynolds LE; Szekeres C; Lamar J; Batista S; Kostourou V; Germain MA; Reynolds AR; Jones DT; Watson AR; Jones JL; Harris A; Hart IR; Iruela-Arispe ML; Dipersio CM; Kreidberg JA; Hodivala-Dilke KM
Am J Pathol; 2010 Sep; 177(3):1534-48. PubMed ID: 20639457
[TBL] [Abstract][Full Text] [Related]
9. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK.
Oh J; Seo DW; Diaz T; Wei B; Ward Y; Ray JM; Morioka Y; Shi S; Kitayama H; Takahashi C; Noda M; Stetler-Stevenson WG
Cancer Res; 2004 Dec; 64(24):9062-9. PubMed ID: 15604273
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitory effect of recombinant anti-angiogenic peptide of tumstatin on growth and metastasis of human ovarian cancer transplanted in nude mice].
Zhang GM; Sui LH; Jia T; Zhao YZ; Fu SB; Liu XH; Yu Y
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):170-3. PubMed ID: 18756929
[TBL] [Abstract][Full Text] [Related]
11. Sequence motifs of tissue inhibitor of metalloproteinases 2 (TIMP-2) determining progelatinase A (proMMP-2) binding and activation by membrane-type metalloproteinase 1 (MT1-MMP).
Worley JR; Thompkins PB; Lee MH; Hutton M; Soloway P; Edwards DR; Murphy G; Knäuper V
Biochem J; 2003 Jun; 372(Pt 3):799-809. PubMed ID: 12630911
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a novel recombinant myoglobin fusion protein expression system to characterize the tissue inhibitor of metalloproteinase (TIMP)-4 and TIMP-2 C-terminal domain and tails by mutagenesis. The importance of acidic residues in binding the MMP-2 hemopexin C-domain.
Kai HS; Butler GS; Morrison CJ; King AE; Pelman GR; Overall CM
J Biol Chem; 2002 Dec; 277(50):48696-707. PubMed ID: 12374789
[TBL] [Abstract][Full Text] [Related]
13. Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).
Xu X; Mikhailova M; Chen Z; Pal S; Robichaud TK; Lafer EM; Baber S; Steffensen B
Matrix Biol; 2011 Sep; 30(7-8):404-12. PubMed ID: 21839835
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.
Batra J; Robinson J; Soares AS; Fields AP; Radisky DC; Radisky ES
J Biol Chem; 2012 May; 287(19):15935-46. PubMed ID: 22427646
[TBL] [Abstract][Full Text] [Related]
15. Antineoplastic urinary protein inhibits Kaposi's sarcoma and angiogenesis in vitro and in vivo.
Masood R; McGarvey ME; Zheng T; Cai J; Arora N; Smith DL; Sloane N; Gill PS
Blood; 1999 Feb; 93(3):1038-44. PubMed ID: 9920854
[TBL] [Abstract][Full Text] [Related]
16. TIMP-2 disrupts FGF-2-induced downstream signaling pathways.
Seo DW; Kim SH; Eom SH; Yoon HJ; Cho YR; Kim PH; Kim YK; Han JW; Diaz T; Wei BY; Stetler-Stevenson WG
Microvasc Res; 2008 Nov; 76(3):145-51. PubMed ID: 18721821
[TBL] [Abstract][Full Text] [Related]
17. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP).
Zucker S; Drews M; Conner C; Foda HD; DeClerck YA; Langley KE; Bahou WF; Docherty AJ; Cao J
J Biol Chem; 1998 Jan; 273(2):1216-22. PubMed ID: 9422789
[TBL] [Abstract][Full Text] [Related]
18. TIMP-2-derived 18-mer peptide inhibits endothelial cell proliferation and migration through cAMP/PKA-dependent mechanism.
Kim HJ; Cho YR; Kim SH; Seo DW
Cancer Lett; 2014 Feb; 343(2):210-6. PubMed ID: 24252252
[TBL] [Abstract][Full Text] [Related]
19. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
20. Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties.
Maeshima Y; Colorado PC; Kalluri R
J Biol Chem; 2000 Aug; 275(31):23745-50. PubMed ID: 10837460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
